Core Viewpoint - Alphatec Holdings Inc. is identified as a high short interest stock with significant upside potential, driven by its growth strategies and recent partnerships [1]. Group 1: Financial Outlook - TD Cowen has lowered its price target for Alphatec from $27 to $20 while maintaining a Buy rating, indicating a belief that the market has not fully recognized the company's growth potential [1]. - Alphatec's revenue outlook for 2026 is projected to reach $890 million, suggesting strong future growth [1]. Group 2: Strategic Partnerships - On January 12, Alphatec entered a partnership with Theradaptive, acquiring exclusive US commercial rights to market OsteoAdapt, a new osteoinductive bone graft for spinal fusion [2]. - The partnership is structured to provide long-term value through upfront and milestone payments, along with perpetual royalties, aiming to disrupt the $10 billion US spine biologics market [3]. Group 3: Company Overview - Alphatec Holdings Inc. specializes in medical technology for the surgical treatment of spinal disorders, operating both in the US and internationally [4].